Canadian adverse drug reaction newsletters by DugMartin

VIEWS: 106 PAGES: 30

									         Health Santé                                                    Therapeutic Products Programme
         Canada Canada                                             Programme des produits thérapeutiques




              Index: Published
  Canadian Adverse Drug Reaction Newsletters
April 2001; 11(2)
Adverse drug reaction reporting - 2000: Part 1
Antiparkinsonian drugs and “sleep attacks”
Rofecoxib (Vioxx): a year in review
Communiqué - Warfarin and glucosamine: interaction
Drugs of Current Interest

January 2001; 11(1)
Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
Clopidogrel (Plavix): hematological reactions
Gentamicin ear drops and ototoxicity: update
Drugs of Current Interest

October 2000; 10(4)
New influenza drugs: unexpected serious reactions
Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
Abboject® Unit-of-Use Syringe: reports of malfunction
Communiqué - Glucosamine sulfate: hyperglycemia
               - Ketotifen (Zaditen®): sleep apnea
               - Diclofenac (Voltaren Ophtha®) and ketorolac
                   tromethamine (Acular®): corneal ulceration
Drugs of Current Interest

July 2000; 10 (3)
St. John’s wort: harmful drug interaction
Olanzapine (Zyprexa): suspected serious reactions
Sildenafil (Viagra): cardiac risks
New Bureau Name
Communiqué - Citalopram (Celexa) and clarithromycin (Biaxin): interaction
                  - Itraconazole (Sporanox): serum sickness-like disorder
Drugs of Current Interest


                                                                                                           1
April 2000; 10 (2)
Adverse drug reaction reporting - 1999
Celecoxib (Celebrex): 1 year later
Correction - ticlopidine
Communiqué - orlistat (Xenical): pancreatitis
Drugs of Current Interest

January 2000; 10 (1)
Cisapride (Prepulsid): interactions
Pemoline (Cylert): market withdrawal
Bupropion (Zyban): update
Communiqué - HIV protease inhibitors: paronychia
                 - Gingko biloba: bleeding disorders
Drugs of Current Interest

October 1999;9(4)
Serious hematologic reactions associated with ticlopidine - update
Leukotriene receptor antagonists: suspected adverse reactions
Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)
Alteplase (Activase rt-PA) for acute ischemic stroke
Abciximab (ReoPro): risk of acute thrombocytopenia
Nefazodone (Serzone) and hepatotoxicity
Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)
Bupropion (Zyban): suspected adverse reactions
1998 ADR Statistics
Updates: immune globulin IV products, tolcapone (Tasmar)
Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)
Isotretinoin and depression
Low-dose ASA and GI Bleeding
Guidelines for reporting ADRs
Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction




                                                                                       2
October 1998; 8(4)
Recent News About Drug Risks
New Ontario Regional ADR Centre
Discontinuation Reactions Associated With SSRIs
Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)
Quality Information in Spontaneous Reports
Donepezil: Suspected Adverse Reactions
Olanzapine: Hematological Reactions
Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)
Alendronate-induced esophagitis
1997 ADR statistics
Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium,
                   risperidone, venlafaxine hydrochloride

January 1998; 8(1)
Drugs: QT interval prolongation and torsades de pointes
Ciprofloxacin use in epileptic patients taking phenytoin
Appetite suppressants - update
Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)
Calcium-channel blockers
Azithromycin - severe iatrogenic hepatitis
Newsletter survey results
Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)
ACE inhibitors and bronchospasm
Interferon beta-1b
Radiopharmaceuticals
New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)
Adverse drug reaction reporting - 1996
Potential abuse of butorphanol nasal spray
Aminoglycoside ear drops and ototoxicity



                                                                                           3
January 1997; 7(1)
Primary pulmonary hypertension and appetite suppressants
HIV protease inhibitors and increased bleeding in hemophilia?
Erythema multiforme and nifedipine
Congenital anomalies and fluconazole

October 1996; 6(4)
Cefaclor-associated serum sickness-like reaction
Newsletter Assessment - Questionnaire

July 1996; 6(3)
Cisapride: Arrhythmia Awareness
Midazolam: A Wake-Up Call
Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)
Metformin: Lactic Acidosis
Nefazodone: ADR Profile
1995 Statistics
ADR or Product Fault?

January 1996; 6(1)
Cotrimoxazole
Nicotine Patches and exercise
Terbinafine - hepatobiliary reactions
SSRIs - hyponatremia

October 1995; 5(4)
Update: Fertility Drugs
Propofol: Convulsions
Contraindications: Dinoprostone Vaginal Gel
DOCI List

July 1995; 5(3)
Reporting Adverse Drug Reactions
Lamotrigine (Lamictal): rashes
Drug Names: confusion from two fronts
Tiaprofenic Acid: cystitis
Ticlopidine: revisited
DOCI List



                                                                4
April 1995; 5(2)
Zidovudine: Benefits of use during pregnancy
Serevent®: Patient warnings must be stressed
Fluoroquinolones: Tendonitis
Topical Antifungals: Recent switch to over-the-counter
Phenazopyridine: Hemolytic anemia

January 1995; 5(1)
Risperidone and EPS
Sumatriptan and migraine exacerbation
Bromocriptine
Fertility drug awareness
New regional centre for Quebec

October 1994; 4(3)
Regional Centres
New Drugs - Serzone, Neurontin, Sabril
Drugs of current interest

July 1994; 4(2)
Editorial Note
Terbinafine
Herbal preparations

March 1994; 4(1)
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
Antidepressants and Suicide
Help Wanted: Risperdal

November 1993; 3(2)
Ticlopidine HCl - Hematological and Liver Effects
H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)
ACE Inhibitors: Renal Effects
Sumatriptan Succinate: Chest Pain
Nicotine Patches: Update / Inadvertent Exposure




                                                         5
April 1992; 2(1)
ADR Program, 1991 Annual Report
Case Report: Drug Interactions with Omeprazole
Vasospasm with B-Blockers
GI Bleeding with Toradol®

August 1991; 1(2)
PPSP Workshop
Minocycline - Case reports of severe liver and renal reactions
ADRs in the Elderly
Ciprofloxacin - ADR profile
Diclofenac - Hepatic reactions

January 1991; 1(1)
Saskatchewan ADR Pilot Project
The WHO Connection
Working Group on ADR Assessment




                                                                 6
         Health Santé                                                    Therapeutic Products Programme
         Canada Canada                                             Programme des produits thérapeutiques




              Index: Published
  Canadian Adverse Drug Reaction Newsletters
April 2001; 11(2)
Adverse drug reaction reporting - 2000: Part 1
Antiparkinsonian drugs and “sleep attacks”
Rofecoxib (Vioxx): a year in review
Communiqué - Warfarin and glucosamine: interaction
Drugs of Current Interest

January 2001; 11(1)
Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
Clopidogrel (Plavix): hematological reactions
Gentamicin ear drops and ototoxicity: update
Drugs of Current Interest

October 2000; 10(4)
New influenza drugs: unexpected serious reactions
Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
Abboject® Unit-of-Use Syringe: reports of malfunction
Communiqué - Glucosamine sulfate: hyperglycemia
               - Ketotifen (Zaditen®): sleep apnea
               - Diclofenac (Voltaren Ophtha®) and ketorolac
                   tromethamine (Acular®): corneal ulceration
Drugs of Current Interest

July 2000; 10 (3)
St. John’s wort: harmful drug interaction
Olanzapine (Zyprexa): suspected serious reactions
Sildenafil (Viagra): cardiac risks
New Bureau Name
Communiqué - Citalopram (Celexa) and clarithromycin (Biaxin): interaction
                  - Itraconazole (Sporanox): serum sickness-like disorder
Drugs of Current Interest


                                                                                                           1
April 2000; 10 (2)
Adverse drug reaction reporting - 1999
Celecoxib (Celebrex): 1 year later
Correction - ticlopidine
Communiqué - orlistat (Xenical): pancreatitis
Drugs of Current Interest

January 2000; 10 (1)
Cisapride (Prepulsid): interactions
Pemoline (Cylert): market withdrawal
Bupropion (Zyban): update
Communiqué - HIV protease inhibitors: paronychia
                 - Gingko biloba: bleeding disorders
Drugs of Current Interest

October 1999;9(4)
Serious hematologic reactions associated with ticlopidine - update
Leukotriene receptor antagonists: suspected adverse reactions
Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)
Alteplase (Activase rt-PA) for acute ischemic stroke
Abciximab (ReoPro): risk of acute thrombocytopenia
Nefazodone (Serzone) and hepatotoxicity
Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)
Bupropion (Zyban): suspected adverse reactions
1998 ADR Statistics
Updates: immune globulin IV products, tolcapone (Tasmar)
Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)
Isotretinoin and depression
Low-dose ASA and GI Bleeding
Guidelines for reporting ADRs
Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction




                                                                                       2
October 1998; 8(4)
Recent News About Drug Risks
New Ontario Regional ADR Centre
Discontinuation Reactions Associated With SSRIs
Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)
Quality Information in Spontaneous Reports
Donepezil: Suspected Adverse Reactions
Olanzapine: Hematological Reactions
Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)
Alendronate-induced esophagitis
1997 ADR statistics
Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium,
                   risperidone, venlafaxine hydrochloride

January 1998; 8(1)
Drugs: QT interval prolongation and torsades de pointes
Ciprofloxacin use in epileptic patients taking phenytoin
Appetite suppressants - update
Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)
Calcium-channel blockers
Azithromycin - severe iatrogenic hepatitis
Newsletter survey results
Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)
ACE inhibitors and bronchospasm
Interferon beta-1b
Radiopharmaceuticals
New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)
Adverse drug reaction reporting - 1996
Potential abuse of butorphanol nasal spray
Aminoglycoside ear drops and ototoxicity



                                                                                           3
January 1997; 7(1)
Primary pulmonary hypertension and appetite suppressants
HIV protease inhibitors and increased bleeding in hemophilia?
Erythema multiforme and nifedipine
Congenital anomalies and fluconazole

October 1996; 6(4)
Cefaclor-associated serum sickness-like reaction
Newsletter Assessment - Questionnaire

July 1996; 6(3)
Cisapride: Arrhythmia Awareness
Midazolam: A Wake-Up Call
Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)
Metformin: Lactic Acidosis
Nefazodone: ADR Profile
1995 Statistics
ADR or Product Fault?

January 1996; 6(1)
Cotrimoxazole
Nicotine Patches and exercise
Terbinafine - hepatobiliary reactions
SSRIs - hyponatremia

October 1995; 5(4)
Update: Fertility Drugs
Propofol: Convulsions
Contraindications: Dinoprostone Vaginal Gel
DOCI List

July 1995; 5(3)
Reporting Adverse Drug Reactions
Lamotrigine (Lamictal): rashes
Drug Names: confusion from two fronts
Tiaprofenic Acid: cystitis
Ticlopidine: revisited
DOCI List



                                                                4
April 1995; 5(2)
Zidovudine: Benefits of use during pregnancy
Serevent®: Patient warnings must be stressed
Fluoroquinolones: Tendonitis
Topical Antifungals: Recent switch to over-the-counter
Phenazopyridine: Hemolytic anemia

January 1995; 5(1)
Risperidone and EPS
Sumatriptan and migraine exacerbation
Bromocriptine
Fertility drug awareness
New regional centre for Quebec

October 1994; 4(3)
Regional Centres
New Drugs - Serzone, Neurontin, Sabril
Drugs of current interest

July 1994; 4(2)
Editorial Note
Terbinafine
Herbal preparations

March 1994; 4(1)
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
Antidepressants and Suicide
Help Wanted: Risperdal

November 1993; 3(2)
Ticlopidine HCl - Hematological and Liver Effects
H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)
ACE Inhibitors: Renal Effects
Sumatriptan Succinate: Chest Pain
Nicotine Patches: Update / Inadvertent Exposure




                                                         5
April 1992; 2(1)
ADR Program, 1991 Annual Report
Case Report: Drug Interactions with Omeprazole
Vasospasm with B-Blockers
GI Bleeding with Toradol®

August 1991; 1(2)
PPSP Workshop
Minocycline - Case reports of severe liver and renal reactions
ADRs in the Elderly
Ciprofloxacin - ADR profile
Diclofenac - Hepatic reactions

January 1991; 1(1)
Saskatchewan ADR Pilot Project
The WHO Connection
Working Group on ADR Assessment




                                                                 6
         Health Santé                                                    Therapeutic Products Programme
         Canada Canada                                             Programme des produits thérapeutiques




              Index: Published
  Canadian Adverse Drug Reaction Newsletters
April 2001; 11(2)
Adverse drug reaction reporting - 2000: Part 1
Antiparkinsonian drugs and “sleep attacks”
Rofecoxib (Vioxx): a year in review
Communiqué - Warfarin and glucosamine: interaction
Drugs of Current Interest

January 2001; 11(1)
Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
Clopidogrel (Plavix): hematological reactions
Gentamicin ear drops and ototoxicity: update
Drugs of Current Interest

October 2000; 10(4)
New influenza drugs: unexpected serious reactions
Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
Abboject® Unit-of-Use Syringe: reports of malfunction
Communiqué - Glucosamine sulfate: hyperglycemia
               - Ketotifen (Zaditen®): sleep apnea
               - Diclofenac (Voltaren Ophtha®) and ketorolac
                   tromethamine (Acular®): corneal ulceration
Drugs of Current Interest

July 2000; 10 (3)
St. John’s wort: harmful drug interaction
Olanzapine (Zyprexa): suspected serious reactions
Sildenafil (Viagra): cardiac risks
New Bureau Name
Communiqué - Citalopram (Celexa) and clarithromycin (Biaxin): interaction
                  - Itraconazole (Sporanox): serum sickness-like disorder
Drugs of Current Interest


                                                                                                           1
April 2000; 10 (2)
Adverse drug reaction reporting - 1999
Celecoxib (Celebrex): 1 year later
Correction - ticlopidine
Communiqué - orlistat (Xenical): pancreatitis
Drugs of Current Interest

January 2000; 10 (1)
Cisapride (Prepulsid): interactions
Pemoline (Cylert): market withdrawal
Bupropion (Zyban): update
Communiqué - HIV protease inhibitors: paronychia
                 - Gingko biloba: bleeding disorders
Drugs of Current Interest

October 1999;9(4)
Serious hematologic reactions associated with ticlopidine - update
Leukotriene receptor antagonists: suspected adverse reactions
Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)
Alteplase (Activase rt-PA) for acute ischemic stroke
Abciximab (ReoPro): risk of acute thrombocytopenia
Nefazodone (Serzone) and hepatotoxicity
Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)
Bupropion (Zyban): suspected adverse reactions
1998 ADR Statistics
Updates: immune globulin IV products, tolcapone (Tasmar)
Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)
Isotretinoin and depression
Low-dose ASA and GI Bleeding
Guidelines for reporting ADRs
Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction




                                                                                       2
October 1998; 8(4)
Recent News About Drug Risks
New Ontario Regional ADR Centre
Discontinuation Reactions Associated With SSRIs
Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)
Quality Information in Spontaneous Reports
Donepezil: Suspected Adverse Reactions
Olanzapine: Hematological Reactions
Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)
Alendronate-induced esophagitis
1997 ADR statistics
Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium,
                   risperidone, venlafaxine hydrochloride

January 1998; 8(1)
Drugs: QT interval prolongation and torsades de pointes
Ciprofloxacin use in epileptic patients taking phenytoin
Appetite suppressants - update
Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)
Calcium-channel blockers
Azithromycin - severe iatrogenic hepatitis
Newsletter survey results
Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)
ACE inhibitors and bronchospasm
Interferon beta-1b
Radiopharmaceuticals
New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)
Adverse drug reaction reporting - 1996
Potential abuse of butorphanol nasal spray
Aminoglycoside ear drops and ototoxicity



                                                                                           3
January 1997; 7(1)
Primary pulmonary hypertension and appetite suppressants
HIV protease inhibitors and increased bleeding in hemophilia?
Erythema multiforme and nifedipine
Congenital anomalies and fluconazole

October 1996; 6(4)
Cefaclor-associated serum sickness-like reaction
Newsletter Assessment - Questionnaire

July 1996; 6(3)
Cisapride: Arrhythmia Awareness
Midazolam: A Wake-Up Call
Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)
Metformin: Lactic Acidosis
Nefazodone: ADR Profile
1995 Statistics
ADR or Product Fault?

January 1996; 6(1)
Cotrimoxazole
Nicotine Patches and exercise
Terbinafine - hepatobiliary reactions
SSRIs - hyponatremia

October 1995; 5(4)
Update: Fertility Drugs
Propofol: Convulsions
Contraindications: Dinoprostone Vaginal Gel
DOCI List

July 1995; 5(3)
Reporting Adverse Drug Reactions
Lamotrigine (Lamictal): rashes
Drug Names: confusion from two fronts
Tiaprofenic Acid: cystitis
Ticlopidine: revisited
DOCI List



                                                                4
April 1995; 5(2)
Zidovudine: Benefits of use during pregnancy
Serevent®: Patient warnings must be stressed
Fluoroquinolones: Tendonitis
Topical Antifungals: Recent switch to over-the-counter
Phenazopyridine: Hemolytic anemia

January 1995; 5(1)
Risperidone and EPS
Sumatriptan and migraine exacerbation
Bromocriptine
Fertility drug awareness
New regional centre for Quebec

October 1994; 4(3)
Regional Centres
New Drugs - Serzone, Neurontin, Sabril
Drugs of current interest

July 1994; 4(2)
Editorial Note
Terbinafine
Herbal preparations

March 1994; 4(1)
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
Antidepressants and Suicide
Help Wanted: Risperdal

November 1993; 3(2)
Ticlopidine HCl - Hematological and Liver Effects
H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)
ACE Inhibitors: Renal Effects
Sumatriptan Succinate: Chest Pain
Nicotine Patches: Update / Inadvertent Exposure




                                                         5
April 1992; 2(1)
ADR Program, 1991 Annual Report
Case Report: Drug Interactions with Omeprazole
Vasospasm with B-Blockers
GI Bleeding with Toradol®

August 1991; 1(2)
PPSP Workshop
Minocycline - Case reports of severe liver and renal reactions
ADRs in the Elderly
Ciprofloxacin - ADR profile
Diclofenac - Hepatic reactions

January 1991; 1(1)
Saskatchewan ADR Pilot Project
The WHO Connection
Working Group on ADR Assessment




                                                                 6
         Health Santé                                                    Therapeutic Products Programme
         Canada Canada                                             Programme des produits thérapeutiques




              Index: Published
  Canadian Adverse Drug Reaction Newsletters
April 2001; 11(2)
Adverse drug reaction reporting - 2000: Part 1
Antiparkinsonian drugs and “sleep attacks”
Rofecoxib (Vioxx): a year in review
Communiqué - Warfarin and glucosamine: interaction
Drugs of Current Interest

January 2001; 11(1)
Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
Clopidogrel (Plavix): hematological reactions
Gentamicin ear drops and ototoxicity: update
Drugs of Current Interest

October 2000; 10(4)
New influenza drugs: unexpected serious reactions
Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
Abboject® Unit-of-Use Syringe: reports of malfunction
Communiqué - Glucosamine sulfate: hyperglycemia
               - Ketotifen (Zaditen®): sleep apnea
               - Diclofenac (Voltaren Ophtha®) and ketorolac
                   tromethamine (Acular®): corneal ulceration
Drugs of Current Interest

July 2000; 10 (3)
St. John’s wort: harmful drug interaction
Olanzapine (Zyprexa): suspected serious reactions
Sildenafil (Viagra): cardiac risks
New Bureau Name
Communiqué - Citalopram (Celexa) and clarithromycin (Biaxin): interaction
                  - Itraconazole (Sporanox): serum sickness-like disorder
Drugs of Current Interest


                                                                                                           1
April 2000; 10 (2)
Adverse drug reaction reporting - 1999
Celecoxib (Celebrex): 1 year later
Correction - ticlopidine
Communiqué - orlistat (Xenical): pancreatitis
Drugs of Current Interest

January 2000; 10 (1)
Cisapride (Prepulsid): interactions
Pemoline (Cylert): market withdrawal
Bupropion (Zyban): update
Communiqué - HIV protease inhibitors: paronychia
                 - Gingko biloba: bleeding disorders
Drugs of Current Interest

October 1999;9(4)
Serious hematologic reactions associated with ticlopidine - update
Leukotriene receptor antagonists: suspected adverse reactions
Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)
Alteplase (Activase rt-PA) for acute ischemic stroke
Abciximab (ReoPro): risk of acute thrombocytopenia
Nefazodone (Serzone) and hepatotoxicity
Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)
Bupropion (Zyban): suspected adverse reactions
1998 ADR Statistics
Updates: immune globulin IV products, tolcapone (Tasmar)
Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)
Isotretinoin and depression
Low-dose ASA and GI Bleeding
Guidelines for reporting ADRs
Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction




                                                                                       2
October 1998; 8(4)
Recent News About Drug Risks
New Ontario Regional ADR Centre
Discontinuation Reactions Associated With SSRIs
Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)
Quality Information in Spontaneous Reports
Donepezil: Suspected Adverse Reactions
Olanzapine: Hematological Reactions
Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)
Alendronate-induced esophagitis
1997 ADR statistics
Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium,
                   risperidone, venlafaxine hydrochloride

January 1998; 8(1)
Drugs: QT interval prolongation and torsades de pointes
Ciprofloxacin use in epileptic patients taking phenytoin
Appetite suppressants - update
Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)
Calcium-channel blockers
Azithromycin - severe iatrogenic hepatitis
Newsletter survey results
Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)
ACE inhibitors and bronchospasm
Interferon beta-1b
Radiopharmaceuticals
New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)
Adverse drug reaction reporting - 1996
Potential abuse of butorphanol nasal spray
Aminoglycoside ear drops and ototoxicity



                                                                                           3
January 1997; 7(1)
Primary pulmonary hypertension and appetite suppressants
HIV protease inhibitors and increased bleeding in hemophilia?
Erythema multiforme and nifedipine
Congenital anomalies and fluconazole

October 1996; 6(4)
Cefaclor-associated serum sickness-like reaction
Newsletter Assessment - Questionnaire

July 1996; 6(3)
Cisapride: Arrhythmia Awareness
Midazolam: A Wake-Up Call
Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)
Metformin: Lactic Acidosis
Nefazodone: ADR Profile
1995 Statistics
ADR or Product Fault?

January 1996; 6(1)
Cotrimoxazole
Nicotine Patches and exercise
Terbinafine - hepatobiliary reactions
SSRIs - hyponatremia

October 1995; 5(4)
Update: Fertility Drugs
Propofol: Convulsions
Contraindications: Dinoprostone Vaginal Gel
DOCI List

July 1995; 5(3)
Reporting Adverse Drug Reactions
Lamotrigine (Lamictal): rashes
Drug Names: confusion from two fronts
Tiaprofenic Acid: cystitis
Ticlopidine: revisited
DOCI List



                                                                4
April 1995; 5(2)
Zidovudine: Benefits of use during pregnancy
Serevent®: Patient warnings must be stressed
Fluoroquinolones: Tendonitis
Topical Antifungals: Recent switch to over-the-counter
Phenazopyridine: Hemolytic anemia

January 1995; 5(1)
Risperidone and EPS
Sumatriptan and migraine exacerbation
Bromocriptine
Fertility drug awareness
New regional centre for Quebec

October 1994; 4(3)
Regional Centres
New Drugs - Serzone, Neurontin, Sabril
Drugs of current interest

July 1994; 4(2)
Editorial Note
Terbinafine
Herbal preparations

March 1994; 4(1)
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
Antidepressants and Suicide
Help Wanted: Risperdal

November 1993; 3(2)
Ticlopidine HCl - Hematological and Liver Effects
H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)
ACE Inhibitors: Renal Effects
Sumatriptan Succinate: Chest Pain
Nicotine Patches: Update / Inadvertent Exposure




                                                         5
April 1992; 2(1)
ADR Program, 1991 Annual Report
Case Report: Drug Interactions with Omeprazole
Vasospasm with B-Blockers
GI Bleeding with Toradol®

August 1991; 1(2)
PPSP Workshop
Minocycline - Case reports of severe liver and renal reactions
ADRs in the Elderly
Ciprofloxacin - ADR profile
Diclofenac - Hepatic reactions

January 1991; 1(1)
Saskatchewan ADR Pilot Project
The WHO Connection
Working Group on ADR Assessment




                                                                 6
         Health Santé                                                    Therapeutic Products Programme
         Canada Canada                                             Programme des produits thérapeutiques




              Index: Published
  Canadian Adverse Drug Reaction Newsletters
April 2001; 11(2)
Adverse drug reaction reporting - 2000: Part 1
Antiparkinsonian drugs and “sleep attacks”
Rofecoxib (Vioxx): a year in review
Communiqué - Warfarin and glucosamine: interaction
Drugs of Current Interest

January 2001; 11(1)
Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
Clopidogrel (Plavix): hematological reactions
Gentamicin ear drops and ototoxicity: update
Drugs of Current Interest

October 2000; 10(4)
New influenza drugs: unexpected serious reactions
Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
Abboject® Unit-of-Use Syringe: reports of malfunction
Communiqué - Glucosamine sulfate: hyperglycemia
               - Ketotifen (Zaditen®): sleep apnea
               - Diclofenac (Voltaren Ophtha®) and ketorolac
                   tromethamine (Acular®): corneal ulceration
Drugs of Current Interest

July 2000; 10 (3)
St. John’s wort: harmful drug interaction
Olanzapine (Zyprexa): suspected serious reactions
Sildenafil (Viagra): cardiac risks
New Bureau Name
Communiqué - Citalopram (Celexa) and clarithromycin (Biaxin): interaction
                  - Itraconazole (Sporanox): serum sickness-like disorder
Drugs of Current Interest


                                                                                                           1
April 2000; 10 (2)
Adverse drug reaction reporting - 1999
Celecoxib (Celebrex): 1 year later
Correction - ticlopidine
Communiqué - orlistat (Xenical): pancreatitis
Drugs of Current Interest

January 2000; 10 (1)
Cisapride (Prepulsid): interactions
Pemoline (Cylert): market withdrawal
Bupropion (Zyban): update
Communiqué - HIV protease inhibitors: paronychia
                 - Gingko biloba: bleeding disorders
Drugs of Current Interest

October 1999;9(4)
Serious hematologic reactions associated with ticlopidine - update
Leukotriene receptor antagonists: suspected adverse reactions
Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)
Alteplase (Activase rt-PA) for acute ischemic stroke
Abciximab (ReoPro): risk of acute thrombocytopenia
Nefazodone (Serzone) and hepatotoxicity
Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)
Bupropion (Zyban): suspected adverse reactions
1998 ADR Statistics
Updates: immune globulin IV products, tolcapone (Tasmar)
Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)
Isotretinoin and depression
Low-dose ASA and GI Bleeding
Guidelines for reporting ADRs
Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction




                                                                                       2
October 1998; 8(4)
Recent News About Drug Risks
New Ontario Regional ADR Centre
Discontinuation Reactions Associated With SSRIs
Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)
Quality Information in Spontaneous Reports
Donepezil: Suspected Adverse Reactions
Olanzapine: Hematological Reactions
Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)
Alendronate-induced esophagitis
1997 ADR statistics
Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium,
                   risperidone, venlafaxine hydrochloride

January 1998; 8(1)
Drugs: QT interval prolongation and torsades de pointes
Ciprofloxacin use in epileptic patients taking phenytoin
Appetite suppressants - update
Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)
Calcium-channel blockers
Azithromycin - severe iatrogenic hepatitis
Newsletter survey results
Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)
ACE inhibitors and bronchospasm
Interferon beta-1b
Radiopharmaceuticals
New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)
Adverse drug reaction reporting - 1996
Potential abuse of butorphanol nasal spray
Aminoglycoside ear drops and ototoxicity



                                                                                           3
January 1997; 7(1)
Primary pulmonary hypertension and appetite suppressants
HIV protease inhibitors and increased bleeding in hemophilia?
Erythema multiforme and nifedipine
Congenital anomalies and fluconazole

October 1996; 6(4)
Cefaclor-associated serum sickness-like reaction
Newsletter Assessment - Questionnaire

July 1996; 6(3)
Cisapride: Arrhythmia Awareness
Midazolam: A Wake-Up Call
Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)
Metformin: Lactic Acidosis
Nefazodone: ADR Profile
1995 Statistics
ADR or Product Fault?

January 1996; 6(1)
Cotrimoxazole
Nicotine Patches and exercise
Terbinafine - hepatobiliary reactions
SSRIs - hyponatremia

October 1995; 5(4)
Update: Fertility Drugs
Propofol: Convulsions
Contraindications: Dinoprostone Vaginal Gel
DOCI List

July 1995; 5(3)
Reporting Adverse Drug Reactions
Lamotrigine (Lamictal): rashes
Drug Names: confusion from two fronts
Tiaprofenic Acid: cystitis
Ticlopidine: revisited
DOCI List



                                                                4
April 1995; 5(2)
Zidovudine: Benefits of use during pregnancy
Serevent®: Patient warnings must be stressed
Fluoroquinolones: Tendonitis
Topical Antifungals: Recent switch to over-the-counter
Phenazopyridine: Hemolytic anemia

January 1995; 5(1)
Risperidone and EPS
Sumatriptan and migraine exacerbation
Bromocriptine
Fertility drug awareness
New regional centre for Quebec

October 1994; 4(3)
Regional Centres
New Drugs - Serzone, Neurontin, Sabril
Drugs of current interest

July 1994; 4(2)
Editorial Note
Terbinafine
Herbal preparations

March 1994; 4(1)
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
Antidepressants and Suicide
Help Wanted: Risperdal

November 1993; 3(2)
Ticlopidine HCl - Hematological and Liver Effects
H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)
ACE Inhibitors: Renal Effects
Sumatriptan Succinate: Chest Pain
Nicotine Patches: Update / Inadvertent Exposure




                                                         5
April 1992; 2(1)
ADR Program, 1991 Annual Report
Case Report: Drug Interactions with Omeprazole
Vasospasm with B-Blockers
GI Bleeding with Toradol®

August 1991; 1(2)
PPSP Workshop
Minocycline - Case reports of severe liver and renal reactions
ADRs in the Elderly
Ciprofloxacin - ADR profile
Diclofenac - Hepatic reactions

January 1991; 1(1)
Saskatchewan ADR Pilot Project
The WHO Connection
Working Group on ADR Assessment




                                                                 6

								
To top